Fitness Trends Asia Pacific Newborn Screening Market

Asia Pacific Newborn Screening Market - Size,
Share, Outlook, and Opportunity Analysis, 2018-
2026
Newborn screening has evolved from a simple urine or blood screening test to a more
comprehensive and complex screening system capable of detecting over 50 different conditions.
Newborn screening tests measure a number of markers in infant’s blood that can be either
decreased or increased if an infant has certain diseases. Currently, conditions such as cystic
fibrosis (CF), congenital hypothyroidism, phenylketonuria (PKU), and around 22 other metabolic
conditions that affect protein or fat metabolism can be diagnosed through newborn screening
tests.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2546
Market Dynamics
Demand for newborn screening is increasing in order to tackle various infectious diseases such
as measles, mumps, polio, tuberculosis, rubella, influenza, whooping cough, chickenpox,
malaria, and streptococcal pharyngitis. According to the World Health Organization (WHO)
2018, globally, around 86% of infants are vaccinated against 26 diseases, however, 19.5 million
infants are unvaccinated resulting in death of 2-3 million children every year.
Screening of newborn is rapidly gaining traction in Asia Pacific region, owing to highest birth
rate in the region, which is almost half of the global population. Therefore, countries in Asia
Pacific are focusing on arranging various workshops to discuss and find solutions for increasing
incidence of neonatal diseases. For instance, from March 30–April 1, 2008, PerkinElmer, Inc.
arranged a workshop on consolidating newborn screening efforts in Cebu, Philippines, in Asia
Pacific region. From June 4-5 in 2010, PerkinElmer, Inc. arranged another workshop in Manila,
Philippines, which included workshop participants such as service providers, policy-makers,
consumer advocates, and researchers from 11 different countries.
Increasing engagement programs by various government healthcare regulatory bodies for
newborn screening and its deployment for wider population base are expected to drive growth